

07 Jan 2019 | News

QUOTED. Jan. 7, 2019. Bonnie Anderson.

by

Diagnostics firm Veracyte signed a deal to combine clinical study cohorts with Johnson & Johnson to accelerate development of two nasal swab tests for early detection of lung cancer. See how CEO Bonnie Anderson describes the arrangement here.

"Having access to these cohorts with clinical truth labels that can be used to benchmark our tests' performance is important as it means we don't have to build this critical resource from scratch."

– Bonnie Anderson, CEO, Veracyte

- Find out more: [Johnson & Johnson Joins Forces With Veracyte For Lung Cancer Diagnostics](#)

[Click here](#) for a free trial of *Medtech Insight*